29 June, 2015.
AMAG Pharmaceuticals (Waltham, MA) is to acquire Cord Blood Registry (CBR; San Bruno, CA) for $700 million. Founded in 1992, CBR is the world’s largest newborn stem cell company; according to AMAG's press release, its acquisition of CBR will "expand AMAG's suite of maternal health offerings and add a high-margin business with complementary commercial capabilities and attractive future growth opportunities to [its] portfolio". CBR owns a state-of-the-art storage facility that houses more than 600,000 preserved umbilical cord blood and tissue stem cell units, which represents more than half of all privately stored cord units in the U.S. In 2014, the company generated pro forma revenue of approximately $126 million and adjusted EBITDA of$45 million. The deal is expected to close in Q3.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.